Accessibility Menu
Eli Lilly logo

Eli Lilly

(NYSE) LLY

Current Price$1,173.20
Market Cap$1.10TMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1970)+192,338%
5 Year+427%
1 Year+49%
1 Month+4%
Eli Lilly last closing stock price
MetricPriceDate
Last closeUSD 1,169.172026-07-16
Eli Lilly stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.93%USD 1,216.952026-07-09
1 month+4.16%USD 1,122.502026-06-16
3 month+26.34%USD 925.442026-04-17
Year to date+9.16%USD 1,071.052025-12-31
1 year+49.08%USD 784.252025-07-16
3 year+167.11%USD 437.712023-07-17
5 year+427.25%USD 221.752021-07-16
Since inception+192,337.61%USD 0.611970-07-09

Eli Lilly Financials at a Glance

Market Cap

$1.10TMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$72.25B

Net Income (TTM)

$25.28B

EPS (TTM)

$27.78

P/E Ratio

42.09

Dividend

$6.46

Beta (Volatility)

0.59 (Low)

Price

$1,173.20

Volume

66,120

Open

$1,156.60

Previous Close

$1,169.17

Daily Range

$1,150.63 - $1,187.95

52-Week Range

$623.78 - $1,249.45

Estimated Earnings Date

Aug 5, 2026

LLY News

Eli Lilly and Novo Nordisk logos

Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win

Prosper Junior BakinyJul 17, 2026
Healthcare stocks - GettyImages-1412197515-1500x1000-6b42342

Why AtaiBeckley Stock Soared Today

Joe TenebrusoJul 16, 2026
office_building_commercial_real_estate

5 Best Commercial Real Estate Stocks for 2026

Kristi WaterworthJul 16, 2026
TMF-Pills-Blue-StockVStock.png

Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026?

Brendan CoffeyJul 16, 2026
GettyImages-pensive investor at computer

Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market?

Adria CiminoJul 14, 2026
LLY-stock

Here's How Much Eli Lilly's Weight-Loss Drugs Are Worth to Investors

Daniel SparksJul 13, 2026
Scientists happy

Should You Buy Eli Lilly Stock? Here's My Honest Take.

Keith SpeightsJul 11, 2026
GettyImages-2163791811

Record Numbers of Americans Are on GLP-1 Drugs. That's Great News for This Stock.

Matthew BenjaminJul 9, 2026
Page 1

LLY: Motley Fool Moneyball Superscore

89

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Eli Lilly

Lilly makes medicines for diabetes, cancer, and mental health conditions. Its products help people manage chronic diseases and improve daily life. Many patients and healthcare providers rely on Lilly’s treatments for essential care.

Pill Bottles and Beyond: What Lilly Sells

  • Cardiometabolic Health (49% of revenue in 2024): Diabetes and obesity medicines for adults, including Mounjaro, Trulicity, and Zepbound.

Growth Spurts: How Lilly Got Here

  • Launched Zepbound for obesity in the U.S. in November 2023.
  • Acquired Morphic Holding (inflammatory bowel disease pipeline) in 2024.
  • Expanded manufacturing with new sites in North Carolina, Wisconsin, Ireland, Germany, and Indiana since 2023.
  • Formed partnerships with Boehringer Ingelheim, Incyte, AbCellera, and others to co-develop medicines.
  • Launched LillyDirect, a digital health platform, in the U.S. in 2024.

What Makes Lilly Stand Out in the Crowd

Lilly operates in about 95 countries, distributing through major wholesalers and pharmacies. The company invests heavily in research, with around 11,000 employees in development roles. Its broad patent portfolio and manufacturing expansion support its position in diabetes, obesity, and cancer care.

Five Things You Need to Know

  • Revenue was $45.04 billion in 2024, up 32% from 2023.
  • Cardiometabolic health products made up 49% of 2024 revenue.
  • Net income was $10.59 billion in 2024, up 102% from 2023.
  • Operating cash flow was $8.82 billion in 2024, up 108% from 2023.

Bottom Line

Lilly has grown by focusing on diabetes, obesity, and cancer medicines. Its strong pipeline, global reach, and manufacturing investments support continued adaptation in a changing healthcare market.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

50,000

CEO

David A. Ricks, MBA

Website

www.lilly.com

Headquarters

Indianapolis, IN 46285, US

LLY Financials

Key Financial Metrics (TTM)

Gross Margin

83.51%

Operating Margin

45.87%

Net Income Margin

34.98%

Return on Equity

101.30%

Return on Capital

43.01%

Return on Assets

21.68%

Earnings Yield

2.38%

Dividend Yield

0.55%

Payout Ratio

22.10%

Stock Overview

Market Cap

$1.10TMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

941.74M

Volume

66.12K

Avg. Volume

3.26M

Financials (TTM)

Gross Profit

$60.33B

Operating Income

$33.14B

EBITDA

$33.46B

Operating Cash Flow

$20.48B

Capital Expenditure

-$6.90B

Free Cash Flow

$13.58B

Cash & ST Invst.

$5.28B

Total Debt

$43.37B

Eli Lilly Performance Analysis

Eli Lilly annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 28,541,400,0000.8%
20232023-12-31USD 34,124,100,00019.6%
20242024-12-31USD 45,042,700,00032.0%
20252025-12-31USD 65,179,000,00044.7%
Eli Lilly sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3022.2%
Q32025-09-3013.1%
Q42025-12-319.6%
Q12026-03-312.6%
Eli Lilly annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 6.9012.8%
20232023-12-31USD 5.80-16.0%
20242024-12-31USD 11.71101.9%
20252025-12-31USD 22.9595.9%
Eli Lilly sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30105.6%
Q32025-09-30-1.3%
Q42025-12-3119.0%
Q12026-03-3111.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$19.80B

+55.5%

Gross Profit

$16.22B

+54.4%

Gross Margin

81.93%

N/A

Market Cap

$1.10TMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$22.02M

N/A

Employees

50,000

N/A

Net Income

$7.40B

+168.0%

EBITDA

$9.69B

+132.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$5.28B

+64.0%

Total Debt

$43.37B

+12.6%

Accounts Receivable

$21.18B

+51.2%

Inventory

$14.53B

+56.0%

Long Term Debt

$39.37B

+14.1%

Short Term Debt

$4.00B

-0.4%

Return on Assets

21.68%

N/A

Return on Invested Capital

41.45%

N/A

Free Cash Flow

$3.01B

+287.8%

Operating Cash Flow

$5.33B

+220.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
JNJJohnson & Johnson
$252.87+1.16%
ABBVAbbVie Inc.
$255.71+0.52%
MRKMerck & Co., Inc.
$127.42-0.16%
NVSNovartis AG
$153.32+0.39%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$15.08-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$68.24-0.04%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$29.02+0.05%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$42.35+0.04%

Questions About LLY

What is the current price of Eli Lilly?

Eli Lilly is trading at $1,173.20 per share.

What is the 52-week range for Eli Lilly?

Over the past 52 weeks, Eli Lilly has traded between $623.78 and $1,249.45.

How much debt does Eli Lilly have?

As of the most recent reporting period, Eli Lilly reported total debt of $43.37B.

How much cash does Eli Lilly have on hand?

Eli Lilly reported $5.14B in cash and cash equivalents in its most recent financial results.

What is Eli Lilly’s dividend yield?

Eli Lilly currently has a dividend yield of 0.55%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services